The Alport Syndrome Foundation (ASF), the Pedersen Family and the Kidney Foundation of Canada (KFOC) have announced that there are new funds available for researchers working to increase knowledge of Alport syndrome. The program anticipates awarding two research grants worth $100,000 each. The funding programs are…
Reata Pharmaceuticals has a new clinical plan for the approval of bardoxolone methyl in the treatment of chronic kidney disease (CKD) caused by Alport syndrome. Last month, the U.S. Food and Drug Administration (FDA) provided guidance to Reata scientists, suggesting that a single pivotal trial with a…
A research team led by Prof. Hirofumi Kai from Kumamoto University in Japan has been awarded an international research grant from the Alport Syndrome Foundation, an organization based in the U.S. The Alport Syndrome Research Funding Program was established in 2010 and has selected one or two projects…
The Alport Syndrome Foundation (ASF) has announced that it is accepting applications from Alport syndrome patients, ages 16-22, for the Paul Silver Tribute Award, an up to $1,000 prize that can be used by winners to further a wanted and life-enriching activity, from schooling to summer camp. The award…
The Alport Syndrome Foundation (ASF), the leading non-profit organization in the U.S. serving the Alport syndrome community, is encouraging young patients to apply for the Paul Silver Tribute Award. The deadline for submissions is on Nov. 4. The award aims to enrich the lives of patients between…
Get regular updates to your inbox.